TRAIL was further inversely associated with tumor stage, with higher concentrations in women diagnosed with stage 0 breast cancer or carcinoma in situ, and HER2 + breast cancer molecular subtype. The gene discussed is TNFSF10; the disease is in situ carcinoma.